La maladie de Parkinson (MP) est caractérisée par une perte dopaminergique dans le striatum, structure sous-corticale impliquée dans le contrôle moteur, la mémoire et les comportements émotionnels. Les interneurones cholinergiques (ChIs) striataux jouent un rôle clef dans cette réorganisation pathologique du striatum en modulant l’activité des neurones de projection striataux (MSNs). Ce travail vise à étudier l’implication des ChIs et des récepteurs muscariniques (mAChRs) dans les mécanismes qui sous-tendent l’expression des déficits moteurs, cognitifs et émotionnels dans différents modèles de la MP chez la souris. L’inhibition optogénétique des ChIs réduit les déficits moteurs (akinésie, asymétrie posturale, déficit sensori-moteur). Les enregistrements électrophysiologiques montrent que l’inhibition des ChIs réduit l’excitabilité des MSNs et rétablit l’équilibre d’activité des deux voies de sortie striatale. Ces effets antiparkinsoniens sont reproduits par le blocage pharmacologique striatal des mAChRs M1 et M4. Ils sont dus à une action préférentielle de l’ACh sur les mAChRs au niveau des MSNs à l’origine de la voie striatonigrale puisqu’ils disparaissent chez des souris invalidées pour les récepteurs M4 exprimés dans ces neurones. La photoinhibition des ChIs réduit les déficits mnésiques et l’anxiété. L’antagoniste des mAChRs M1 réduit l’anxiété mais est inefficace sur les déficits mnésiques, suggérant que d’autres récepteurs cholinergiques striataux puissent être engagés dans les fonctions mnésiques. L’ensemble de nos résultats apporte un éclairage nouveau sur l’implication des ChIs striataux dans le fonctionnement physiologique et pathologique du striatum. / Parkinson’s disease (PD) is characterized by a dopamiergic loss into the striatum, a subcortical structure involved in motor control, memory and emotional behaviors. Striatal cholinergic interneurons (ChIs) play a key role in this pathological reorganization of the striatal circuitry by modulating striatal projection neurons (MSNs). This study aims to investigate the involvement of ChIs and muscarinic receptors (mAChRs) in the mechanisms underlying the expression of motor, cognitive and emotional deficits observed in different models of PD in mice. ChIs optogenetic inhibition reduced motor deficits (akinesia, postural asymmetry, sensorimotor deficit). Electrophysiological recordings show that ChIs photoinhibition reduces MSNs excitability and restores the balance between the two striatal output pathways. These antiparkinsonian effects are reproduced by pharmacological intrastriatal blockade of M1 and M4 mAChRs. They are due to a preferential action of ACh on mAChRs expressed on striatonigral MSNs since the deficits disappear in mutant mice that lack M4 mAChRs only in these neurons. ChIs photoinhibition also reduces memory deficits and anxiety. M1 mAChRs antagonist reduces anxiety but is inefficient on memory deficits, suggesting that other cholinergic receptors might be involved in striatal memory functions. Overall, these results give new insights on the role of cholinergic interneurons in the normal and pathological functioning of the striatum.

Os receptores nicotínicos de acetilcolina (colinérgicos) (nAChRs) neuronais são proteínas integrais de membrana e pertencem à família de canais iônicos controlados por ligante, compostos por subunidades α e β. Esses receptores desempenham um papel-chave na transmissão de sinal entre os neurônios nos sistemas nervoso central e periférico. O subtipo α3β4, por exemplo, é o nAChR neuronal mais expresso no sistema nervoso autônomo; nAChRs contendo a subunidade α3 estão presentes em alta densidade no gânglio cervical superior, glândulas pineal e adrenais. Também estão presentes na substancia nigra, striatum, hipocampo, locus ceruleus, tracto habênulo-interpeduncular e cerebelo. Os nAChRs são inibidos por uma variedade de substâncias químicas, incluindo toxinas naturais, anestésicos locais, drogas de abuso (por, exemplo, cocaína) e compostos clinicamente importantes (tranqüilizantes, por exemplo). O mecanismo de inibição desses receptores tem sido investigado intensivamente. Neste estudo, nós investigamos o mecanismo pelo qual a tacrina (9-1,2,3,4-tetraidroaminoacridina), um agente usado clinicamente no tratamento da doença de Alzheimer, inibe o nAChR α3β4 de rato recombinante expresso nas células KXα3β4R2, utilizando uma técnica de cinética química rápida. A constante de dissociação da nicotina do sítio que controla a ativação do receptor, Kd, é 23 µM e a constante de equilíbrio de abertura do canal, Φ-1, é 4. A tacrina inibe o receptor competitivamente, com um KI de 0,77 µM. / Neuronal nicotinic acetylcholine (cholinergic) receptors (nAChRs) are integral membrane proteins and belong to the family of ligand-gated cation channels composed by α and β subunits. These receptors play a key role in the signal transmission between neurons in the central and peripheral nervous system. The α3β4 subtype, for example, is the most expressed neuronal nAChR in autonomic ganglia; α3-containing nAChRs are present at particularly high density in the superior cervical ganglia, pineal, and adrenal glands. They are also present in the substancia nigra, striatum, hippocampus, locus ceruleus, habenulo-interpeduncular tract and cerebellum. The nAChRs are inhibited by a variety of chemical substances, including natural toxins, local anesthetics, abused drugs (e.g., cocaine) and clinically important compounds (e.g., tranquilizers). The mechanism of inhibition of these receptors has been intensively investigated. In this study, we investigated the mechanism by which tacrine (9-1,2,3,4-tetahydroaminoacridine), an agent used clinically to treat Alzheimers disease, inhibits the recombinant rat α3β4 nAChR expressed in KXα3β4R2 cells, using a rapid chemical kinetic technique. The nicotine dissociation constant for the site controlling receptor activation, Kd, is 23 µM and the channel-opening equilibrium constant, Φ-1, is 4. Tacrine inhibits the receptor competitively, with a KI of 0.77 µM.

Muitos subtipos de receptores são ativados pelo mesmo ligante, mas estão acoplados a diferentes mensageiros secundários podendo produzir sinalização divergente em uma célula, enquanto receptores ativados por diferentes ligantes, mas que compartilham o mesmo mensageiro secundário, podem produzir sinalização convergente. Para examinar as bases mecanísticas que influenciam a proliferação e a diferenciação celular determinamos as funções de liberação intracelular de Ca2+ e a excitabilidade celular mediada pelos receptores purinérgicos e colinérgicos utilizando imageamento de cálcio por microscopia confocal. Para tanto, caracterizamos a participação dos subtipos P2X1-7 e P2Y1,2,4,6 de receptores purinérgicos aos níveis dos transcritos de mRNA e de expressão protéica, assim como pela atividade de induzir os transientes de [Ca2+]i, aumento na concentração livre de cálcio intracelular, durante a diferenciação neuronal de células P19 de carcinoma embrionário, que foram utilizadas como modelo in vitro para o desenvolvimento neuronal precoce. Em células embriônicas os receptores P2Y1,2, P2X4 ou os heteromultímeros de P2X com farmacologia semelhante ao do receptor P2X4 foram os responsáveis pelos transientes de [Ca2+]i induzidos pelo ATP e seus análogos. Ao término da diferenciação neuronal, os receptores P2Y2,6 e P2X2 foram os principais mediadores das respostas de [Ca2+]i. Obtivemos evidências do envolvimento destes receptores na indução da proliferação tanto de células embriônicas como de progenitores neuronais, por ensaios de incorporação de BrdU, e da indução da diferenciação neuronal das células progenitoras, na presença de vários agonistas e antagonistas de receptores purinérgicos. Como resultado desses estudos, a regulação da proliferação e diferenciação celular foi principalmente devida aos subtipos de receptores P2Y1 e P2Y2, já que estes efeitos foram eliminados após a depleção dos depósitos intracelulares de cálcio e pela demonstração de que estes eram os possíveis receptores funcionais. Entre os receptores colinérgicos, fornecemos evidências para a expressão de receptores nicotínicos (nAChRs) e muscarínicos (mAChRs) funcionais durante a diferenciação de células P19. Detectamos a expressão e a atividade dos subtipos de nAChRs formados pelos subtipos α2-α7, β2, β4 e M1-M3 e M5 de mAChRs durante a diferenciação neuronal. As respostas de [Ca2+]i induzidas pelos agonistas dos nAChRs foram observadas em células P19 embriônicas e neuronais. As respostas de [Ca2+]i mediadas pelos receptores muscarínicos, em níveis próximos aos basais em células embriônicas, aumentaram durante a diferenciação. As elevações na [Ca2+]i induzidas pelos nAChRs em células indiferenciadas foram devidas ao influxo de Ca2+ do meio extracelular. Em células diferenciadas em neurônios, os aumentos de transientes de [Ca2+]i induzidos pelos nAChRs foram parcialmente inibidas após o pré-tratamento das células com a rianodina, enquanto as respostas de [Ca2+]i mediadas pelos mAChR não foram afetadas na presença deste composto, sugerindo uma contribuição da liberação de Ca2+ a partir dos depósitos de Ca2+ sensíveis à rianodina para as elevações mediadas pelos nAChRs. Demonstramos também, que a nicotina, agindo através dos nAChRs, inibiu a proliferação em células embriônicas, porém, a induziu em células progenitoras neuronais pela mobilização de Ca2+ dos depósitos intracelulares. A muscarina induziu em células embriônicas o aumento na proliferação via mAChRs acoplados às proteínas Gαq/11, e promoveu a diferenciação neuronal via M2 mAChRs em células precursoras neuronais. Estes dados sugeriram que a acetilcolina agindo via mAChR funciona como um mitógeno que ativa as proteínas quinases de trifosfato de inositol (IP3) e que poderia estar envolvida na síntese de DNA durante os estágios iniciais da neurogênese. Nós ainda provemos evidências que as oscilações de [Ca2+]i são características para cada estágio da diferenciação e são iniciadas pela liberação de Ca2+ mediada pelo IP3. As análises da determinação do fenótipo neuronal na presença de vários inibidores da transdução do sinal induzido pelo cálcio residem na liberação de Ca2+ induzida pelo IP3 é necessária para o progresso da diferenciação neuronal. Assim, os sinais espontâneos de [Ca2+]i são propriedades intrínsecas das células em diferenciação. A modulação de sua freqüência e amplitudes especifica a aquisição de um fenótipo de célula neuronal. / Various receptors subtypes are activated by the same ligand although coupled to different second messengers. These receptors act either by inducing divergent signaling in one cell, whereas in another cell different receptors may stimulate the very same pathways producing convergent signaling. We have characterized intracellular Ca2+- release and -influx mediated by purinergic and cholinergic receptors using calcium imaging by confocal microscopy to evaluate the mechanistic bases which influence cell proliferation and differentiation We have characterized the participation of purinergic subtypes P2X1-7 and P2Y1,2,4,6 receptor subtypes at mRNA transcription and protein expression levels as well as receptor-induced changes in free intracellular calcium concentration ([Ca2+]i) during differentiation of P19 embryonal carcinoma cells as an in vitro model for early neuronal development. The participation of individual P2X and P2Y receptor subtypes in the differentiation process was studied by employing different available purinergic receptor agonists and antagonists. In embryonic cells, P2Y1,2, P2X4 receptors, or P2X-heteromultimers with similar P2X4 pharmacology were responsible for ATP and ATP-analog-induced [Ca2+]i transients. Following completion of neuronal differentiation, P2Y2,6 receptors and P2X2 subtypes were the major mediators of the [Ca2+]i-response. Regulation of cell proliferation and differentiation of P19 embryonic and progenitor cells was mostly due to P2Y1 and P2Y2 receptor activation, as these effects were abolished following depletion of intracellular calcium stores, and they are probably the unique functional P2Y receptors at these stages of differentiation. We also provide evidence for expression of functional nicotinic (nAChRs) and muscarinic acetylcholine receptors (mAChRs) during neuronal differentiation of P19 cells. We have detected expression and activity of nAChRs formed by the subunits α2-α7, β2, β4, and M1-M3 and M5 mAChR subtypes along the differentiation process. Receptor response in terms of nicotinic agonist-evoked Ca2+ flux was observed in embryonic and neuronal-differentiated cells. However, mAChRs-induced calcium responses, merely present in undifferentiated P19 cells, increased during neuronal differentiation. The nAChR-induced [Ca2+]i response in undifferentiated cells was due to Ca2+ influx. However, in differentiated P19 neurons the nAChR-induced [Ca2+]i response was partially inhibited following pretreatment of the cells with ryanodine, while the mAChR-induced response remained unaffected, suggesting the contribution of Ca2+ release from ryanodine-sensitive stores to nAChR- but not mAChR-mediated Ca2+ responses. The presence of functional nAChRs in embryonic cells suggests that these receptors are involved in triggering Ca2+ waves during initial neuronal differentiation. In the present study we have also shown that nicotine, acting via nAChRs, inhibited proliferation in embryonic cells, but induced cell division of progenitor cells by Ca2+ mobilization from internal stores. Stimulation of progenitor cells by muscarine led to an increase in DNA synthesis mainly resulting from activation of Gαq/11-coupled mAChRs. Muscarine as well promoted differentiation of neural precursor cells by activation of M2 mAChRs subtypes. These data suggest that acetylcholine, acting via mAChRs, functions as a mitogen during early neurogenesis. We also provide evidence that oscillations of [Ca2+]i as characteristics for the respective stage of differentiation are initiated by triphosphate inositol (IP3)-mediated Ca2+-release. Neuronal cell fate determination analysis in the presence of various inhibitors of calcium-induced signal transduction underlined that IP3-mediated Ca2+-release is necessary for neuronal differentiation progress. Thus, spontaneous Ca2+-signals are an intrinsic property of differentiating neural precursor cells. Modulation of their frequency and amplitude is believed to direct the acquisition of a defined neuronal phenotype.

Submitted by Nadir Basilio (nadirsb@uninove.br) on 2015-07-27T14:45:59Z No. of bitstreams: 1 Fernando Oliveira Costa.pdf: 1199928 bytes, checksum: f721f323b7b101614061ea44e7dd6cb3 (MD5) / Made available in DSpace on 2015-07-27T14:45:59Z (GMT). No. of bitstreams: 1 Fernando Oliveira Costa.pdf: 1199928 bytes, checksum: f721f323b7b101614061ea44e7dd6cb3 (MD5) Previous issue date: 2014-02-21 / The metabolic syndrome (MetS) consists of a combination of conditions that tend to cluster together, and increase the risk of type 2 diabetes and cardiovascular disease. The components of the metabolic syndrome include central (abdominal) obesity, elevated fasting glucose, dyslipidemia (abnormally high triglycerides and low high-density lipoprotein cholesterol), and elevated blood pressure. MetS is also associated with proinflammatory and prothrombotic states, non-alcoholic liver steatosis, obstructive sleep apnea and reproduction disorders. Although a common unifying physiopathological mechanism is not known, central obesity and inflammation play a major role in MetS and upon each of its components. The MetS has reached epidemic proportions and to date there are no proven pharmacological interventions that simultaneously target all of the components of this syndrome. Inflammation plays an important role in the pathogenesis of the MetS. Recently, it was discovered that inflammation can be regulated by neural, cholinergic mechanisms and a cholinergic drug, the acetylcholinesterase inhibitor galantamine suppresses abnormal inflammation and alleviates MetS pathologies in rodents. The fact that galantamine is an approved drug, used to treat patients with Alzheimer´s disease with a known safety profile, will facilitate its clinical application in another situations. We hypothesize that treatment of subjects with the MetS with galantamine will result in alleviation in the MetS clinical conditions and inflammation. The objective of our study was to initiate an investigation on the safety profile of galantamine in MetS patients, with special attention on autonomic, hemodynamic and cognitive parameters. A randomized, double-blind, prospective study evaluated clinical, autonomic, hemodynamic and cognitive variables of patients with MetS in two moments: before treatment (basal state) and after 28 days of treatment with galantamine 8 mg daily. There was a statistical tendency in reducing systolic blood pressure in the HRV with Finometer® in patients under galantamine (124.4 ± 4 vs 119.7 ± 3.7 mmHg, basal and 28 days values, respectively) and also a reduction in diastolic blood pressure (72.5 ± 1.3 vs 67.2 ± 1.7 mmHg, basal and 28 days values, respectively). Paradoxically, an increase in the sympathetic modulation of the heart was observed with the HRV study measuring the LF (nu) value (46.2 ± 3.8 vs 57.1 ± 3.4 basal and 28 days, respectively) and a decrease in the parasympathetic modulation HF (nu) value (53.8 ± 3.8 vs 43.0 ± 3.4, basal and 28 days, respectively). We did not observe any significant change in cognitive domains. Our conclusion is that treatment with galantamine 8 mg exhibits a safe clinical profile and can be used in MetS patients. / A síndrome metabólica consiste na combinação de condições agrupadas e aumentam o risco para diabetes tipo 2 e doença cardiovascular. Seus componentes incluem obesidade central, níveis aumentados de glicose, dislipidemia caracterizada por aumento de triglicérides e baixos níveis de HDL e aumento da pressão arterial. Também está associada a um estado proinflamatório, a um estado protrombótico, a esteatose hepática não-alcoólica, apnéia obstrutiva do sono e a desordens reprodutivas. Apesar da não determinação de um mecanismo fisiopatológico unificador, obesidade central e inflamação parecem ser centrais na síndrome metabólica e nos seus componentes individuais. A síndrome metabólica tem alcançado proporções epidêmicas universais e até o presente não há intervenção farmacológica comprovada que atue simultaneamente em todos os seus componentes. Sabe-se hoje que o processo inflamatório tem um papel importante na patogenia da síndrome. Recentemente foi evidenciado que a inflamação pode ser regulada por mecanismos neurais colinérgicos, e que a galantamina, um inibidor da acetilcolinesterase, suprime a inflamação e atua nos componentes da síndrome diminuindo a patogenia em roedores. O fato de a galantamina ser uma droga já aprovada e de perfil seguro em portadores de demência facilita seu uso em outras situações clínicas. Considerando a hipótese de que a galantamina causará melhora da inflamação e dos outros distúrbios relacionados, o objetivo deste estudo foi iniciar a investigação sobre o perfil de segurança da galantamina em pacientes com síndrome metabólica, em especial, em parâmetros hemodinâmicos, autonômicos e de cognição. Realizamos um estudo prospectivo, duplo-cego e randomizado, que avaliou os dados clínicos e os parâmetros descritos, no momento basal e após 28 dias de uso de galantanima (8mg por dia), em portadores de síndrome metabólica. Houve uma tendência à redução da PAS, avaliada batimento-a-batimento com o Finometer no grupo que usou galantamina (124,4 ± 4 vs 119,7 ± 3,7 mmHg, respectivamente basal e após 28 dias de uso, p=0,04), o mesmo ocorrendo com a PAD (72,5 ± 1,3 vs 67,2 ± 1,7, p=0,005), respectivamente basal e após 28 dias de uso). De forma paradoxal, ocorreu um aumento da atividade simpática na modulação autonômica para o coração, avaliada por meio do estudo da variabilidade da freqüência cardíaca como atestado por um valor LF (nu) (46,2 ± 3,8 vs 57,1 ± 3,4 , p=0,0005)), e redução da modulação parassimpática, representada pelo valor do HF (nu) (53,8 ± 3,8 vs 43,0 ± 3,4, p=0,0005) respectivamente basal e após 28 dias de uso. Não observamos alterações significativas nos testes que avaliam o domínio cognitivo dos indivíduos. Concluímos que a dose utilizada de galantamina tem um perfil de segurança clínica que permite expandir seu uso em pacientes portadores de síndrome metabólica.

Due to the persisting lack of reliable animal models of cognitive impairment with good translational validity, researches strive to discover new ways and tools to replicate symptoms of human neurodegenerative diseases in rodents. Recently, biperiden, an M1- selective muscarinic antagonist, has been proposed as a potential tool for generating fast screening models of mnemonic deficits such as seen in patients with Alzheimer's disease. Being highly selective for the M1 receptor, a predominant type of muscarinic acetylcholine receptors in the brain involved in cognitive processes, it has been speculated to possibly only influence cognition without causing sensorimotor side effects. Studies assessing the usability of this drug reported conflicting results. We have decided to expand the experimental data and evaluate biperiden's validity in several variants of the Morris water maze. The results of this study showed no significant effect of biperiden on cognitive flexibility, tested by reversal learning. In delayed-matching-to-position paradigm, which tests assesses working memory, we found a difference in performance between the two experimental groups; however, it cannot be unequivocally attributed to a memory impairment. No effects were observed in visible platform task, confirming a lack of...

Recently, the medial habenula-interpeduncular (MHb-IPN) axis has been hypothesized to modulate anxiety although neuronal populations and molecular mechanisms regulating affective behaviors in this circuit are unknown. Here we show that MHb cholinergic neuron activity directly regulates anxiety-like behavior. Optogenetic silencing of MHb cholinergic IPN inputs reduced anxiety-like behavior in mice. MHb cholinergic neurons are unique in that they robustly express neuronal nicotinic acetylcholine receptors (nAChRs), although their role as autoreceptors in these neurons has not been described. nAChRs are ligand-gated cation channels that are activated by the excitatory neurotransmitter, acetylcholine (ACh), as well as nicotine, the addictive component of tobacco smoke. We expressed novel nAChR subunits that render nAChRs hypersensitive to ACh, ACh detectors, selectively in MHb cholinergic neurons of adult mice. Mice expressing these ACh detectors exhibited increased baseline anxiety-like behavior that was alleviated by blocking the mutant receptors. Under stressful conditions, such as during nicotine withdrawal, nAChRs were functionally upregulated in MHb cholinergic neurons mediating an increase in anxiety-like behavior. Together, these data indicate that MHb cholinergic neurons regulate anxiety via signaling through nicotinic autoreceptors and point toward nAChRs in MHb as molecular targets for novel anxiolytic therapeutics.

BACKGROUND: Right ventricular outflow tract (RVOT) is a common source of ventricular tachycardia, which often requires ablation. However, the mechanisms underlying the RVOT's unique arrhythmia susceptibility remain poorly understood due to lack of detailed electrophysiological and molecular studies of the human RVOT. METHODS: We conducted optical mapping studies in 16 nondiseased donor human RVOT preparations subjected to pharmacologically induced adrenergic and cholinergic stimulation to evaluate susceptibility to arrhythmias and characterize arrhythmia dynamics. RESULTS: We found that under control conditions, RVOT has shorter action potential duration at 80% repolarization relative to the right ventricular apical region. Treatment with isoproterenol (100 nM) shortened action potential duration at 80% repolarization and increased incidence of premature ventricular contractions (=0.003), whereas acetylcholine (100 μM) stimulation alone had no effect on action potential duration at 80% repolarization or premature ventricular contractions. However, acetylcholine treatment after isoproterenol stimulation reduced the incidence of premature ventricular contractions (=0.034) and partially reversed action potential duration at 80% repolarization shortening (=0.029). Immunolabeling of RVOT (n=4) confirmed the presence of cholinergic marker VAChT (vesicular acetylcholine transporter) in the region. Rapid pacing revealed RVOT susceptibility to both concordant and discordant alternans. Investigation into transmural arrhythmia dynamics showed that arrhythmia wave fronts and phase singularities (rotors) were relatively more organized in the endocardium than in the epicardium (=0.006). Moreover, there was a weak but positive spatiotemporal autocorrelation between epicardial and endocardial arrhythmic wave fronts and rotors. Transcriptome analysis (n=10 hearts) suggests a trend that MAPK (mitogen-activated protein kinase) signaling, calcium signaling, and cGMP-PKG (protein kinase G) signaling are among the pathways that may be enriched in the male RVOT, whereas pathways of neurodegeneration may be enriched in the female RVOT. CONCLUSIONS: Human RVOT electrophysiology is characterized by shorter action potential duration relative to the right ventricular apical region. Cholinergic right ventricular stimulation attenuates the arrhythmogenic effects of adrenergic stimulation, including increase in frequency of premature ventricular contractions and shortening of wavelength. Right ventricular arrhythmia is characterized by positive spatial-temporal autocorrelation between epicardial-endocardial arrhythmic wave fronts and rotors that are relatively more organized in the endocardium.

Vitronectin (VTN) is a glycoprotein enriched in the blood and activates integrin receptors. VTN blood levels increase only in female mice 24 h after an ischemic stroke and exacerbate brain injury through IL-6-driven inflammation, but the VTN induction mechanism is unknown. Here, a 30 min middle cerebral artery occlusion (MCAO) in female mice induced VTN protein in the liver (normally the main source) in concert with plasma VTN. Male mice were excluded as VTN is not induced after stroke. MCAO also increased plasma VTN levels after de novo expression of VTN in the liver of VTN female mice, using a hepatocyte-specific (SERPINA1) promoter. MCAO did not affect SERPINA1 or VTN mRNA in the liver, brain, or several peripheral organs, or platelet VTN, compared to sham mice. Thus, hepatocytes are the source of stroke-induced increases in plasma VTN, which is independent of transcription. The cholinergic innervation by the parasympathetic vagus nerve is a potential source of brain-liver signaling after stroke. Right-sided vagotomy at the cervical level led to increased plasma VTN levels, suggesting that VTN release is inhibited by vagal tone. Co-culture of hepatocytes with cholinergic neurons or treatment with acetylcholine, but not noradrenaline (sympathetic transmitter), suppressed VTN expression. Hepatocytes have muscarinic receptors and the M1/M3 agonist bethanechol decreased VTN mRNA and protein release in vitro via M1 receptors. Finally, systemic bethanechol treatment blocked stroke-induced plasma VTN. Thus, VTN translation and release are inhibited by muscarinic signaling from the vagus nerve and presents a novel target for lessening detrimental VTN expression.

The therapeutic benefits attributed to activation of peripheral mechanoreceptors are poorly understood. There is growing evidence that mechanical stimulation modulates substrates in the supraspinal central nervous system (CNS) that are outside the canonical somatosensory circuits. This work demonstrates that activation of peripheral mechnoreceptors via mechanical stimulation (MStim) is sufficient to increase dopamine release in the nucleus accumbens (NAc), alter neuron firing rate in the ventral tegmental area (VTA) and increase membrane translocation of delta opioid receptors (DORs) in the NAc. Further, we demonstrate that these effects are dependent on DORs and acetylcholine receptors. Additionally, MStim can block neuronal markers of chronic ethanol dependence including ethanol-induced changes to VTA GABA neuron firing during withdrawal, and DA release profiles after reinstatement ethanol during withdrawal. These are presented in tandem with evidence that MStim also ameliorates behavioral indices of ethanol withdrawal. Finally, exercise, a modality that includes a mechanosensory component, is shown to alter expression of kappa opioid receptors (KORs) in the NAc. This change substantively depresses KORs influence over evoked DA release in direct contraversion to the effects of chronic ethanol. These changes translate into reduced drinking behavior.

No description available.